Rapport Therapeutics, Inc. has announced the successful completion of a significant public offering that raised approximately $382.5 million. This funding comes from two concurrent offerings: a common stock offering and a convertible senior notes offering. The capital raised will primarily support ongoing clinical trials and research initiatives for the company’s lead product, RAP-219, as well as for general corporate purposes.

The common stock offering, which closed on October 30, 2026, involved the sale of 8,333,334 shares of common stock at a public offering price of $21.00 per share. In addition, the company offered pre-funded warrants to purchase an aggregate of 1,190,476 shares of common stock at a price of $20.999 each. The underwriting agreement also included an option for underwriters to purchase an additional 1,428,571 shares, which they exercised in full, bringing the total gross proceeds from the stock offering to around $215.7 million.

Simultaneously, Rapport Therapeutics issued $172.5 million in convertible senior notes due 2032, which included an over-allotment option. The notes bear an interest rate of 2.25% per annum and will be convertible into common stock at an initial conversion price of approximately $26.775 per share. The net proceeds from this offering are estimated to be about $166.8 million.

This dual offering strategy reflects a growing trend among biotech firms to secure funding through both equity and debt instruments, allowing them to maintain flexibility in capital management while advancing their clinical pipelines. The proceeds from these offerings are expected to fund Rapport’s ongoing clinical trials for RAP-219, aimed at treating drug-resistant focal onset seizures, as well as other research and development activities.

Rapport Therapeutics, Inc., incorporated in Delaware, operates in the pharmaceutical preparations industry, identified under SIC code 2834. The company is listed on the Nasdaq under the ticker symbol RAPP. The recent filings indicate that the company is actively engaged in expanding its product offerings and enhancing its research capabilities.

The SEC filing (accession number 0001193125-26-441851) details the terms of the underwriting agreements and the intended use of proceeds, emphasizing the company’s commitment to advancing its clinical trials and exploring potential acquisitions or investments in complementary technologies.

As the pharmaceutical industry continues to evolve, Rapport’s strategic financial moves may influence competitors and set a precedent for funding approaches in the sector. The successful execution of these offerings not only strengthens Rapport's financial position but also enhances its ability to compete in a rapidly changing market.

Looking ahead, the company plans to utilize the raised funds to support its operational needs through the end of 2029, although it acknowledges that its estimates are based on assumptions that may change. The filing does not specify any immediate next steps following this capital raise.